Publication

Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.

Authors not recorded

Oncogene2011PMID 21132006PMC7213757stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (5)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 5

cancerMalignant Neoplasmcivic_curation1.00
drugDacomitinibcivic_curation1.00
drugErlotinibcivic_curation1.00
geneEGFRcivic_curation1.00
variantEGFR L858Rcivic_curation1.00

Curated evidence

Evidence citing this paper (7)

civicCuratedShowing 1–7 of 7 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR A767_V769dupASV2
Dacomitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	submitted	EID12421 In an in vitro study, MCF-7 cells expressing the EGFR A767_V769dup mutation demonstrated sensitivity to dacomitinib (PF00299804), with YFP-EGFR-ICD relocation observed at 10 nM. In comparison, cells e… (full text at CIViC) PMID 21132006 · Harada et al., 2011 · Open in CIViC	civic
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	—	submitted	EID4666 In an in vitro study, a MCF-7 cell line expressing EGFR A767_V769dup mutation demonstrated resistance to erlotinib treatment, compared to MCF-7 cells expressing a known erlotinib sensitizing mutation … (full text at CIViC) PMID 21132006 · Harada et al., 2011 · Open in CIViC	civic
EGFR N771delinsGY2
Dacomitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	submitted	EID12420 In an in vitro study, MCF-7 cells expressing the EGFR N771delinsGY (N771GY) mutation demonstrated sensitivity to dacomitinib (PF00299804), with YFP-EGFR-ICD relocation observed at 50 nM. In comparison… (full text at CIViC) PMID 21132006 · Harada et al., 2011 · Open in CIViC	civic
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	—	submitted	EID4671 In a stage III lung adenocarcinoma patient of African-American descent with EGFR N771>GY mutation, EGFR N771>GY was reported to be resistant to erlotinib treatment. The patient was treated with 4 cycl… (full text at CIViC) PMID 21132006 · Harada et al., 2011 · Open in CIViC	civic
EGFR S768N1
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	—	submitted	EID4272 Cells expressing EGFR harboring the S768N mutation were resistant to erlotinib treatment of up to 3uM, as measured using an in vitro fibril formation assay. This contrasts with cells expressing the L8… (full text at CIViC) PMID 21132006 · Harada et al., 2011 · Open in CIViC	civic
EGFR T790M1
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	—	submitted	EID3809 In an in vitro study, a MCF-7 cell line expressing EGFR L858R and T790M co-mutation demonstrated resistance to erlotinib treatment, compared to MCF-7 cells expressing a known erlotinib sensitizing mut… (full text at CIViC) PMID 21132006 · Harada et al., 2011 · Open in CIViC	civic
EGFR L858R1
Dacomitinib + ErlotinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID4285 In an in vitro study, a MCF-7 cell line expressing EGFR L858R mutation demonstrated sensitivity to erlotinib or dacomitinib (PF00299804) treatment, compared to MCF-7 cells expressing EGFR wild-type. S… (full text at CIViC) PMID 21132006 · Harada et al., 2011 · Open in CIViC	civic